RG-101: Completed Phase II enrollment

Regulus completed enrollment of 78 patients in a Phase II trial evaluating 2 mg/kg subcutaneous RG-101 followed by an approved once-daily direct-acting-antiviral (DAA) for 28 days and a second dose of...